Description
Antibody-drug conjugates (ADCs) are transforming oncology treatment, delivering potent therapies with precision, delivering new hope in combating cancer by directly targeting malignant cells while minimizing damage to healthy tissue and achieving success in ADC manufacturing, means navigating a complex, multi-step development process.
At PCI, we believe that selecting the right CDMO for your new ADC is as important as selecting the right ADC components. As a partner, we offer stability, quality, strategic alignment and a forward-thinking approach in the development and manufacturing of your ADC product, supported by full, temperature-controlled packaging, storage and distribution services from our clinical packaging sites globally.